ABBV · News · 20261106N
Regulatory Risk
AbbVie Inc. · 2026-11-06 · Importance 44 · Surprise 42 · In source text
A government-set price for AbbVie’s drug Vraylar is scheduled to take effect in 2027. The report does not identify the government or disclose the price or estimated financial impact. It notes that Vraylar sales are declining and that the company’s growth depends largely on Skyrizi and Rinvoq.
Key facts
- A government-set price is scheduled to take effect on AbbVie's Vraylar in 2027. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | committed | — | A government-set price is scheduled to take effect on AbbVie's Vraylar in 2027. |